Trials / Terminated
TerminatedNCT00092287
Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
A Phase III, Prospective, Multicenter, Randomized, Open, Parallel Group Comparison of Lanreotide Autogel® (90 and 120 mg) Administered by Deep Subcutaneous Injection Every Four Weeks, With Sandostatin LAR Depot (20 and 30 mg) Administered by Intramuscular Injection, Every Four Weeks for Six Months, in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to compare the efficacy and safety of lanreotide Autogel and Sandostatin LAR Depot, to see whether these two 28-day prolonged release formulations produce a similar clinical response in patients with carcinoid syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lanreotide Autogel (somatostatin analogue) | |
| DRUG | Sandostatin long acting release (LAR) Depot (somatostatin analogue) |
Timeline
- Start date
- 2004-07-01
- Completion
- 2004-10-01
- First posted
- 2004-09-27
- Last updated
- 2020-04-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00092287. Inclusion in this directory is not an endorsement.